Five Prime Therapeutics Inc. has entered into research and commercial agreements with BioWa Inc. and Lonza to use their Potelligent CHOK1SV cell line for the research, development, and production of multiple proprietary antibodies in FivePrime’s oncology pipeline.

Potelligent CHOK1SV is a host cell line for manufacturing recombinant antibodies that combines the power of BioWa’s engineered glycosylation Potelligent Technology with the advantages of Lonza’s proprietary GS Gene Expression System, which includes the industry-leading CHOK1SV cell line.

“The combination of the clinical validation seen with other Potelligent antibodies and the track record of the GS cell line were key to our decision to select this system to enhance the potential for therapeutic efficacy of our emerging pipeline of antibodies in oncology,” said Michael Kavanaugh, MD, Senior Vice President, Research and Development of FivePrime.

The Potelligent CHOK1SV Cell Line retains the desirable features of a high-producing cell line (robust, high-yielding, scalable), with the advantage of a proven bioprocess platform for the CHOK1SV cell line. Antibodies produced by this cell line exhibit enhanced antibody dependent cellular cytotoxicity (ADCC) and can exert potent cytotoxic effects even when their target antigen is low. In addition, they work in whole blood and retain all other desirable features of common antibodies.

The Potelligent CHOK1SV cell line is available under a license to Lonza customers as an option in cell line construction service offering.

Date: June 13, 2012
Source: Five Prime Therapeutics Inc.